| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Estrogen receptor alpha (ERα): binding affinity +79.71 kcal/mol (calculated lowest binding affinity from molecular docking) [1].
|
|---|---|
| ln Vitro |
- In the E-screen assay using MCF-7 human breast cancer cells, Puerarin-4'-O-β-D-glucopyranoside (compound 8) was tested for estrogen-like activity at concentrations of 5, 10, and 50 μM. The compound showed weak or negligible proliferative effects compared to genistein (10) [1].
- Molecular docking study indicated that diglycosylated isoflavones including Puerarin-4'-O-β-D-glucopyranoside exhibited low binding affinities to ERα, possibly due to hydroxy group substitutions in sugar moieties (Table 1) [1]. |
| Enzyme Assay |
Molecular docking simulation was performed to evaluate the binding interaction between Puerarin-4'-O-β-D-glucopyranoside and the estrogen receptor alpha ligand-binding domain. The three-dimensional structure of the ligand was constructed and energy-minimized using MM2 with Chem 3D pro 12.0 software. The crystal structure of ERα co-crystallized with genistein was obtained from the RCSB protein data bank (PDB ID: 1X7R). Chain A of ERα was prepared for docking by removing the other chain and all non-standard residues including genistein using UCSF Chimera 1.11. Protein and ligand files were prepared following the AutoDock Protocol. Docking analysis was carried out using AutoDock 4.2.6 and AutoDock Tools 1.5.6. Putative hydrogen bonding and visual inspection were analyzed with UCSF Chimera 1.11. The calculated lowest binding affinity of Puerarin-4'-O-β-D-glucopyranoside to ERα was +79.71 kcal/mol [1].
|
| Cell Assay |
E-screen assay: ER-positive MCF-7 human breast cancer cells were seeded in 24-well plates at 2×10⁴ cells per well in RPMI1640 medium with 10% FBS, 100 μg/mL streptomycin, and 100 U/mL penicillin for 24 hours. Cells were then treated with the indicated concentrations (5, 10, 50 μM) of test samples including Puerarin-4'-O-β-D-glucopyranoside in phenol red-free RPMI medium supplemented with 5% charcoal-dextran-stripped human serum for 144 hours. In antagonist experiments, 100 nM ICI 182,780 (ER antagonist) was added together with the test samples. Cell proliferation was measured by adding Ez-Cytox reagents and reading absorbance at 450 nm using a microplate reader. The results for compound 8 are presented in Fig. 4H, showing no significant increase in MCF-7 cell proliferation compared to control [1].
|
| References | |
| Additional Infomation |
Puerarin-4'-O-β-D-glucopyranoside is a diglycosylated isoflavone isolated from Pueraria lobata root. It is one of ten isoflavonoids (compounds 1–10) obtained from the n-BuOH fraction that exhibited the highest estrogenic activity among all solvent-partitioned fractions. The compound’s low ERα binding affinity (+79.71 kcal/mol) suggests that glycosylation at the 4'-O position may reduce estrogen receptor interaction compared to aglycone isoflavones such as genistein [1].
|
| Molecular Formula |
C27H30O14
|
|---|---|
| Molecular Weight |
578.519
|
| Exact Mass |
578.163
|
| CAS # |
117047-08-2
|
| PubChem CID |
101259161
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-1.8
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
41
|
| Complexity |
939
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O
|
| InChi Key |
GZFMKWZQYRIRBD-WIQAIWCDSA-N
|
| InChi Code |
InChI=1S/C27H30O14/c28-7-15-19(32)21(34)23(36)26(40-15)17-14(30)6-5-12-18(31)13(9-38-25(12)17)10-1-3-11(4-2-10)39-27-24(37)22(35)20(33)16(8-29)41-27/h1-6,9,15-16,19-24,26-30,32-37H,7-8H2/t15-,16-,19-,20-,21+,22+,23-,24-,26+,27-/m1/s1
|
| Chemical Name |
7-hydroxy-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3-[4-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7285 mL | 8.6427 mL | 17.2855 mL | |
| 5 mM | 0.3457 mL | 1.7285 mL | 3.4571 mL | |
| 10 mM | 0.1729 mL | 0.8643 mL | 1.7285 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
